Patents Examined by Gailene Gabel
-
Patent number: 11099181Abstract: Among other things, two or more different antibodies are caused to bind to one or more units of a chemical component in a sample. Each of the antibodies is attached to one or more beads (e.g., microbeads). The sample is situated on a surface of an image sensor. At the image sensor, light is received originating at a light source that is other than the beads. The received light includes light reflected by, refracted by, or transmitted through the beads. At least one image of the sample is processed to separately enumerate individual beads and complexes of two or more of the beads attached to the two or more antibodies that are bound to a unit of the chemical component. The results of the processing are used to identify a presence or a level of the chemical component in the sample.Type: GrantFiled: May 6, 2020Date of Patent: August 24, 2021Inventor: Alan Marc Fine
-
Patent number: 11061031Abstract: Among other things, a method comprises imaging a sample displaced between a sensor surface and a surface of a microscopy sample chamber to produce an image of at least a part of the sample. The image is produced using lensless optical microscopy, and the sample contains at least blood from a subject. The method also comprises automatically differentiating cells of different types in the image, generating a count of one or more cell types based on the automatic differentiation, and deriving a radiation dose the subject has absorbed based on the count.Type: GrantFiled: April 3, 2020Date of Patent: July 13, 2021Inventor: Alan Marc Fine
-
Patent number: 11060964Abstract: Provided is a cell detection method which makes it possible to effectively and accurately perform gene analysis only on target cells. The cell detection method includes a sorting step of obtaining first information derived from cells in a sample solution by using a flow cytometry method and sorting target cells into a container having arrays of wells each having an opening based on the first information, an imaging step of imaging the cells sorted into the container, and a determination step of obtaining second information derived from cells based on the image of the cells captured by the imaging step and determining cells to be analyzed from the sorted cells.Type: GrantFiled: September 7, 2018Date of Patent: July 13, 2021Assignee: FUJIFILM CorporationInventor: Yasuhisa Kaneko
-
Patent number: 11061024Abstract: Disclosed are methods and systems for analyte detection in a sample and more particularly, a biological sample. Methods and systems particularly relate to differentiating and/or identifying cell types in biological samples, such as blood samples, by adding antibodies specific to predetermined CD antigens. Other methods and systems relate to controlling the dynamic range of an assay for analyte detection.Type: GrantFiled: April 27, 2016Date of Patent: July 13, 2021Assignee: SENZO HEALTH LIMITEDInventors: Aron Rachamim, Jacob Raby
-
Patent number: 11047858Abstract: A method for detecting and typing rare tumor cells having high metabolic activity in a body fluid sample, comprising the following steps: incubating nucleated cells in a body fluid sample with a first metabolic marker and a second metabolic marker capable of producing fluorescence signals; detecting, by means of high-throughput imaging, uptake of all the fluorescence signals of the metabolic markers by cells, so as to determine the energy metabolism mode and intensity of the cells; and identifying and typing, according to the fluorescence signals of the metabolic marker combination, tumor cells having high metabolic activity in the body fluid sample. Further provided is a kit used for the detecting and typing method, comprising a microwell array chip, a first metabolic marker and a second metabolic marker capable of producing fluorescence signals, and fluorescence-labeled antibodies specific to leukocyte common antigen.Type: GrantFiled: May 5, 2020Date of Patent: June 29, 2021Assignee: Suzhou Junhui Biotechnology Co., Ltd.Inventors: Qihui Shi, Yuliang Deng, Yin Tang, Zhuo Wang
-
Patent number: 11028363Abstract: Subpopulations of spore-like cells expressing specific cell surface and gene expression markers are provided. In one embodiment, the cells express at least one cell surface or gene expression marker selected from the group consisting of Oct4, nanog, Zfp296, cripto, Gdf3, UtF1, Ecat1, Esg1, Sox2, Pax6, nestin, SCA-1, CD29, CD34, CD90, B1 integrin, cKit, SP-C, CC10, SF1, DAX1, and SCG10. Also provided are methods for purifying a subpopulation of spore-like cells of interest from a population of spore-like cells, and methods for inducing differentiation of the isolated spore-like cells into cells of endodermal, mesodermal or ectodermal origin. The spore-like cells can be used to generate cells originating from all three germ layers and can be used to treat a patient who has a deficiency of functional cells in any of a wide variety of tissues, including the retina, intestine, bladder, kidney, liver, lung, nervous system, or endocrine system.Type: GrantFiled: June 18, 2018Date of Patent: June 8, 2021Assignee: VCELL THERAPEUTICS, INC.Inventors: Martin P. Vacanti, Charles A. Vacanti
-
Patent number: 11022606Abstract: A cell information acquisition method may include: binding a binding substance to a receptor on a cell membrane surface of a cell, the binding substance being bindable to the receptor; permeabilizing a cell membrane of the cell after the binding; labeling a receptor in an intracellular area of the cell with a binding substance labeled with a first labeling substance after the permeabilizing; causing a specimen including the cell to flow through a flow path after the labeling; irradiating the cell included in the specimen flowing through the flow path with light; and acquiring a signal based on light generated from the first labeling substance in the cell irradiated with light.Type: GrantFiled: October 24, 2017Date of Patent: June 1, 2021Assignee: SYSMEX CORPORATIONInventors: Keiko Yoshikawa, Yuma Oka, Shingo Fujiyama
-
Patent number: 11016106Abstract: A specific and sensitive in vitro ELISA assay and diagnostic test kit is disclosed for determining levels of NT-proBNP protein in a variety of bodily fluids, non-limiting examples of which are blood, serum, plasma, urine and the like. The NT-proBNP ELISA assay test employs the sandwich ELISA technique to measure circulating NT-proBNP in human plasma. In order to obtain antibodies with specific binding properties for targeted amino acid sequences within human proBNP, recombinant human proBNP (or rhproBNP) was expressed and purified for use as an immunogen. Polyclonal antibodies (PAb) to specific amino acid sequences were subsequently purified from goat serum by sequential affinity purification. Monoclonal antibodies were raised against specific polypeptides. Recombinant human NT-proBNP (or rhNT-proBNP) was expressed and purified in order to obtain material for use in calibration of a quantitative method for measurement of human NT-proBNP.Type: GrantFiled: June 13, 2016Date of Patent: May 25, 2021Assignee: NEXUS DX, INC.Inventors: Michelle Davey, George Jackowski, Peter Kupchak, Eric Stanton
-
Patent number: 11016101Abstract: The present invention relates a simple method for evaluating free eukaryotic cell nuclei for biomarkers of DNA damage and/or transcription factor activation, activity, or expression levels and/or epigenetic modifications to chromatin or chromatin-associated factors. The invention also teaches useful strategies for combining nuclear biomarkers into a matrix of endpoints that are capable of elucidating genotoxicants' primary mode of DNA-damaging activity. Kits for conducting methods according to the invention are also described.Type: GrantFiled: October 31, 2018Date of Patent: May 25, 2021Assignee: LITRON LABORATORIES LTD.Inventors: Stephen D. Dertinger, Steven M. Bryce, Jeffrey C. Bemis
-
Patent number: 11002660Abstract: The present invention provides an apparatus for analyzing particles in a solution including a unit configured to place a flow cell having a flow path for flowing a sample solution containing the particles; a unit configured to illuminate the sample solution flowing through the flow path of the flow cell; a photodetector that detects a scattered light and/or fluorescence generated from the particles in the sample solution; and a unit configured to analyze the particles based on their signal intensities detected by the photodetector, wherein the flow cell has the flow path formed in a substrate, a reflection plane is formed on the side surface of the flow path, the reflection plane leads the lights generated in the flow path of the flow cell and advancing in the substrate in-plane direction to a specified region of the surface of the flow cell, and the photodetector detects the light exiting from the specified region to the outside.Type: GrantFiled: April 16, 2018Date of Patent: May 11, 2021Assignee: ON-CHIP BIOTECHNOLOGIES CO., LTD.Inventor: Kazuo Takeda
-
Patent number: 10996216Abstract: The present invention relates to a method for applying a principle of Deterministic Lateral Displacement (DLD), and for separating cells depending on the particle sizes on the basis of the DLD principle after capturing targeted cells or untargeted cells on a carrier and thereby increasing particle sizes.Type: GrantFiled: February 26, 2016Date of Patent: May 4, 2021Assignee: TOPPAN PRINTING CO., LTD.Inventor: Noriaki Arai
-
Patent number: 10983123Abstract: Provided herein are compositions, methods and uses that relate to or result from the identification of markers that can distinguish between cells at different stages of pluripotency. Certain embodiments provide markers that can distinguish between parental cells (i.e. differentiated cells), partially pluripotent (i.e. partially reprogrammed) and pluripotent (i.e. fully reprogrammed cells). Also provided here are uses of such differential markers, for example, in identification of cell potential, in diagnostics, in differential separation, and in creating efficient workflows that involve fewer steps and lesser time in identifying or separating a desired reprogrammed clone or cell line from a mixture of cells at various stages of pluripotency. In certain embodiments, the activity of these markers can be manipulated to influence cell potential for research or medical purposes.Type: GrantFiled: July 27, 2018Date of Patent: April 20, 2021Assignee: Life Technologies CorporationInventors: Uma Lakshmipathy, Rene Quintanilla, Joanna Asprer
-
Patent number: 10962541Abstract: In one embodiment, the invention provides a method of diagnosing sepsis or a virus-related infection (often a viral hemorrhagic fever infection) in a subject by detecting and measuring the level of a set of sepsis and virus infection-associated-GTPase biomarkers in a sample obtained from the subject using multiplexed flow cytometry. Related kits are also provided. In a preferred embodiment, the invention provides point of care diagnostic methods for determining an early stage sepsis or the severity of a virus infection, especially in a hospital or other setting.Type: GrantFiled: February 7, 2019Date of Patent: March 30, 2021Assignee: UNM Rainforest InnovationsInventors: Tione Buranda, Jacob Ongudi Agola, Soumik BasuRay, Scarlett Swanson, Angela Wandinger-Ness, Peter C. Simons, Virginie Bondu
-
Patent number: 10955418Abstract: Methods for single cell analysis by determining the presence and/or amount of one or more target molecules in a plurality of cells may include: (i) immobilizing said plurality of cells on a solid substrate, wherein the cells are immobilized in form of a monolayer; (ii) determining the position of the individual immobilized cells on the solid substrate; (iii) measuring the auto-fluorescence of the individual immobilized cells; (iv) contacting the immobilized cells with a first detection reagent comprising (a) a moiety that specifically recognizes and binds a first target molecule and (b) a fluorescent label under conditions that allow binding of the detection reagent to the first target molecule; (v) measuring the fluorescence of the fluorescent label of the detection reagent bound to the first target molecule for the individual immobilized cells; (vi) determining the presence and/or amount of the first target molecule in the individual immobilized cells by comparing the fluorescence measured in step (v) withType: GrantFiled: September 19, 2017Date of Patent: March 23, 2021Assignee: Zellkraftwerk GmbHInventor: Christian Hennig
-
Patent number: 10955067Abstract: Methods and systems are provided for a microfluidic cartridge including a high performance actuator useful for analyte detection, labeling and analysis. Microfluidic processing systems are to carry out chemical or biochemical reactions, or sequences of reactions, with small volumes (typically between 1 microliter and 10 milliliters) of reactants and products. A microfluidic processing system can comprise a network of tubes interfaced with discrete components such as valves and sensors, or an integrated device made of plastic, glass, metal, or other materials, or a combination of materials, with components such as valves and sensors built into the device and connected by flow passageways formed in the material.Type: GrantFiled: March 3, 2014Date of Patent: March 23, 2021Assignee: Wave 80 Biosciences, Inc.Inventors: Daniel Laser, Amy Droitcour, Hailemariam Negussie, William Behnke-Parks
-
Patent number: 10955415Abstract: The invention relates to methods, kits and compositions using CD247 as a biomarker for assessing the efficacy and selecting an appropriate therapy such as chemotherapeutic, biological therapy or combined therapy for treating a subject suffering from a pathologic disorder that leads to a chronic-inflammatory condition.Type: GrantFiled: September 27, 2012Date of Patent: March 23, 2021Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Michal Baniyash, Julia Kanterman, Moshe Sade-Feldman, Eliran Ish-Shalom
-
Patent number: 10948420Abstract: The systems and methods contained herein are directed toward automated analysis of agglutination reactions to determine properties of materials, including viruses and vaccines thereto. Advanced digital imaging and processing techniques are used to determine the presence or absence of viruses or antibodies within a fluid sample. The systems and methods are versatile, and can be used to determine specific properties of biomaterials and viruses, such as titer value, concentration, genotype, phenotype, serotype, vaccine efficacy, viral resistance and other properties of relevance in the medical, research and development fields. Also provided are systems and methods of standardization, repeatability, and data storage and transmittal to reduce errors and subjectivity inherent to conventional assays characterized by human readers.Type: GrantFiled: December 9, 2016Date of Patent: March 16, 2021Assignee: INDEVR, INC.Inventors: Kathy L. Rowlen, Garrett Wilson, Gregory Yamada, Andrew Smolak, Goran Rauker, Jeffrey T. Ives
-
Patent number: 10948486Abstract: The present invention provides a microporous membrane for detecting at least one target analyte in a sample. The membrane includes an array that comprises at least one capture element and at least one control element printed on the membrane surface, at least one capture element corresponding to and being able to bind a target analyte, the plurality of control elements, when present including: i) at least one fiduciary marker, ii) at least one negative control to monitor background signal, iii) at least one negative control to monitor assay specificity, iv) at least one positive colorimetric control, and v) at least one positive control to monitor assay performance or any combination thereof.Type: GrantFiled: April 18, 2017Date of Patent: March 16, 2021Assignee: Pictor LimitedInventor: Sarita Kumble
-
Patent number: 10942171Abstract: The invention relates to the field of flow cytometry and more particularly to a panel of antibody reagents conjugated to fluorescent compounds. Provided are reagent compositions, comprising at least eight distinct fluorochrome-conjugated antibodies comprising a set of at least there identification antibodies for the identification of a leukocyte population of interest and at least four characterization antibodies for further characterization and/or classification of said leukocyte population. Also provided are kits and methods related to the reagent compositions.Type: GrantFiled: December 20, 2017Date of Patent: March 9, 2021Assignee: Erasmus University Medical Center RotterdamInventors: Jacobus Johannes Maria van Dongen, Jose Alberto Orfao de Matos Correia e Vale, Juan Alejandro Flores-Montero, Julia Maria Almeida Parra, Vincent Henricus Johannes van der Velden, Sebastian Böttcher, Andrew Craig Rawstron, Ruth Mary de Tute, Ludovic Bernard Simon Lhermitte, Vahid Asnafi, Ester Mejstrikova, Tomasz Szczepanski, Paulo Jorge Monteiro Da Silva Lucio, Marta Martín Ayuso, Carlos Eduardo Pedreira
-
Patent number: 10942178Abstract: A device detects a target molecule in a sample in a sample container to measure the target molecule. A first particle is functionalized with a first binding molecule capable of specifically binding to said target molecule. A surface structure includes a second binding molecule. The surface structure covers a flat sensor or is present on a second particle. The first particle is capable of binding the second binding molecule of the surface structure directly or indirectly. The first and/or second binding molecule is indirectly attached to the particle surface of the first and/or second particle and/or the flat sensor surface via a long and rigid linker molecule. A length and a consistency of the linker molecule is selected such as to result in an average extension length of the linker of more than 60 nm. A number of particle clusters or of bound particles is directly or inversely related to an amount of the target molecules present in the sample.Type: GrantFiled: November 13, 2012Date of Patent: March 9, 2021Assignee: Koninklijke Philips N.V.Inventors: Toon Hendrik Evers, Maatje Koets